Daily Chart

Send a Tweet

$NVS
#Novartis Ag-adr
NVS
Novartis Ag-adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-adr right now.

Know someone who is an insider on Novartis Ag-adr?
Let us know.

Novartis Ag-adr - NVS information

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company?s Alcon division provides various eye care products consisting of ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as offer biotech manufacturing services to other companies. The company?s Vaccines and Diagnostics division provides human vaccines and blood testing and molecular diagnostics products. This division sells influenza, meningococcal, pediatric, and traveler vaccines; and nucleic acid technology blood-screening products to prevent the spread of infectious diseases. The company?s Consumer Health division consists of two divisions, including over-the-counter medicines that offer readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland....
www.novusenergy.ca
22 Employees
Last Reported Date: 04/25/13
Last C$0.89 CAD
Change Today +0.02 / 2.30%
Volume 278.3K
As of 3:59 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).

novus energy inc (NVS) Snapshot

Open
C$0.84
Previous Close
C$0.87
Day High
C$0.89
Day Low
C$0.83
52 Week High
01/18/13 - C$1.18
52 Week Low
06/28/12 - C$0.60
Market Cap
168.5M
Average Volume 10 Days
390.2K
EPS TTM
C$0.05
Shares Outstanding
189.4M
EX-Date
--
P/E TM
17.8x
Dividend
--
Dividend Yield
--
NVS:CN Historical Stock Quote
NVS:CN Advanced Stock Chart

Related News

No related news articles were found.

novus energy inc (NVS) Related News

No Related News Found
[addPosition2]

novus energy inc (NVS) Key Developments

Novus Energy Inc. Reports Audited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2012

Novus Energy Inc. reported audited consolidated financial results for the fourth quarter and full year ended December 31, 2012. For the quarter, production revenue was $21,322,000 against $21,187,000 for the same period of last year. Funds flow from operations was $11,655,000 against $12,025,000 for the same period of last year. Funds flow from operations per basic and diluted share was $0.06 against $0.07 for the same period of last year. Net income was $1,111,000 against loss of $2,176,000 for the same period of last year. Net income per basic and diluted share was $0.01 against loss of $0.01 for the same period of last year. Capital expenditures, net was $29,146,000 against $11,684,000 for the same period of last year. The company ended the 2012 fiscal year with net debt of $78.9 million, against lines of credit of $105 million. Funds flow from operations increased 60% to $41.7 million from $26.1 million a year ago. Funds flow from operations per basic and diluted share increased 47% to $0.22 from $0.15 per share in 2011. Net income for the year ended December 31, 2012 was $6.8 million, compared to a loss of $0.8 million a year ago. The company ended 2012 with net debt of $78.9 million against available lines of credit of $105 million. Net income per basic and diluted share was $0.04. Production revenue was $75,952,000 against $53,137,000 for the same period of last year. Capital expenditures, net was $87,306,000 against $73,110,000 for the same period of last year.

Novus Energy Inc. Announces Production Results for the Fourth Quarter and Year Ended December 31, 2012

Novus Energy Inc. announced production results for the fourth quarter and year ended December 31, 2012. For the fourth quarter, the company achieved production of 3,444 boe/d, a 21% increase over fourth quarter 2011 average production volumes of 2,845 boe/d. 2012 average annual production was 3,059 boe/d, a 55% increase over 2011 average annual production volumes of 1,971 boe/d. The Company drilled a total of 72 wells (72.0 net) in 2012 all targeting Viking oil within the Dodsland region of Saskatchewan. Twenty-four of these wells (24.0 net) were drilled in the fourth quarter of 2012. For the full year, the company reported average production for 2012 was 3,059 boe/d, representing 55% year over year average production volume growth. Novus achieved production of 3,444 boe/d in the fourth quarter of 2012 (78% oil and liquids) representing a 21% increase over fourth quarter 2011 production volumes. The preliminary estimate of first quarter 2013 average production based on field estimates is 4,090 boe/d. Operating netbacks in 2012 for the Company's Viking light oil production in Dodsland were estimated to be $54.16/boe. During 2012 Novus operated the drilling of 72 wells all using horizontal multi stage frac technology. During the first quarter of 2013 Novus drilled 17 wells all using horizontal multi stage frac technology. Twenty wells were completed and brought on production during the quarter. Novus currently controls 219 net sections of Viking rights, and has a risked drilling inventory of 1,585 net, undrilled Viking oil locations.

Novus Energy Inc. Announces Production Results for the Month, Fourth Quarter and Year Ended December 2012

Novus Energy Inc. announced production results for the month, fourth quarter and year ended December 2012. For the month, the company's average production during was 3,925 boe/d. For the quarter, the company reported average production was volumes averaged 3,530 boe/d. For the year, the company's corporate exit rate production target of 4,200 boe/d.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:CN C$0.89 CAD +0.02

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVS.
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.9x
Price/Sales 2.4x
Price/Book 1.2x
Price/Cash Flow 4.7x
TEV/Sales 1.3x
 | 

Post a JobJobs

  • Corporate Chief Information Officer
    New York, NY |
    Posted: May 17
  • Product Manager - Consumer Team
    San Francisco, CA | Yelp
    Posted: May 02
  • Product Manager - Local Business Products
    San Francisco, CA | Yelp
    Posted: May 02
  • PART-TIME FACULTY FOR PROGRAMS IN BUSINESS
    New York, NY | New York University
    Posted: Apr 19
Simply Hired

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.